Recipharm, a global CDMO, has acquired Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners, and prominent advanced therapy CDMO, Ampersand-backed Arranta Bio. The acquisitions build on Recipharm’s service offerings in new biologic modalities and form a cornerstone to its strategy of providing drug developers in the Biologics market with scientifically differentiated…
Home Healthcare Markets International News Sweden: Recipharm builds on service offering with acquisitions of Vibalogics and Arranta...